Conduit Capital Limited Overview
Conduit Capital is a small South African investment holding company. After 2015 it was rebuilt as a value-investing insurance holding company on a "float plus equity portfolio" model. In practice it was dominated by one operating asset: the Constantia Insurance Group. Constantia was a niche short- and long-term insurer writing health, medical malpractice, specialty and general property-and-casualty, funeral and assistance business in South Africa and 18 other African countries. CICL generated about 94.4% of group revenue (H1 FY2022). It was placed under curatorship by the Prudential Authority in July 2022 and into provisional liquidation in September 2022. That left Conduit with a run-off life insurer, minority private stakes and a portfolio of legal claims and disputes. Its management now pursues a stated strategy of realising assets and cutting costs. The JSE removed the listing in December 2025 after more than three years of suspension. Conduit is best understood today as a sub-scale, unlisted wind-down vehicle with contingent litigation assets and liabilities. It is no longer an operating insurer.
The company's own description
In IAR22, Conduit describes itself as a listed investment holding company on the JSE Limited, incorporated and domiciled in South Africa. Its stated vision is to grow long-term intrinsic value per share faster than the market average and ahead of its peers. The company website describes a vision of building a diversified investment group. It says the group operates mainly through two internal investment strategies, Insurance and Private Investments. ShareData's summary fact sheet, which predates the liquidation, describes Conduit as an investment holding company whose subsidiaries mostly operate in Southern African insurance. That earlier aim was to build a diversified insurance investment group alongside a non-insurance, value-oriented portfolio.
Business model as it operated (2015 – July 2022)
From June 2015 under CEO Sean Riskowitz, Conduit ran on a model modelled on Berkshire Hathaway. A Value Investors Club write-up in September 2016 called it a "mini-Berkshire":
-
Insurance float generation. Constantia wrote niche gross premium through underwriting management agencies (UMAs), brokers and agents. Much of the risk was ceded under "solvency relief" reinsurance arrangements. These arrangements cut net written premium sharply but also cut the regulatory capital Constantia needed to hold. At 31 December 2021, float was R618.2 million (Interim H1 FY2022).
-
Value-investing capital allocation. Float and shareholder capital were invested on Graham and Buffett principles: fractional ownership, "Mr Market", margin of safety and circle of competence (IAR22, section III). The listed equity portfolio was valued at R125.2 million at 31 December 2021.
-
Private investments. These included 51% of Century 21 South Africa, Africa Special Opportunity Capital (ASOC) Fund I, insurtech stakes held through Conduit Ventures, and a 30% stake in Oraclemed Health Investments (acquired for R42.0 million in H1 FY2022).
Revenue model
| Revenue type | Description | Status |
|---|---|---|
| Insurance premium (short-term) | Gross premium on health, medical malpractice, P&C specialty, P&C general, guarantee, liability and assistance business written by CICL | Ceased July 2022 (curatorship, then liquidation) |
| Insurance premium (long-term) | Life, funeral and group risk through Constantia Life Limited (CLL) and Constantia Life & Health Assurance Company (CLAH) | CLL in run-off; CLAH sale to Affinity Financial Services (R20 million) announced December 2022, completion not confirmed in sources reviewed |
| Investment income | Dividends, interest and fair-value movements on listed and unlisted holdings | Ongoing on a reduced asset base |
| Franchise / brokerage income | Consolidated through the 51% stake in Century 21 South Africa (master franchise) | Status after 2022 not publicly disclosed |
| Commissions / administration | Earned through Constantia Risk and Insurance Holdings (CRIH) group entities | Largely ceased |
The model was transactional insurance underwriting. There was no subscription or licensing revenue. In the value chain, CICL was a risk carrier: the licensed insurer behind third-party UMAs and binder holders. The group also held minority stakes in some of those distribution and claims businesses through Conduit Ventures.
Customer types and end markets
Constantia insured individuals (gap cover and primary health products, funeral and life), professionals (medical practitioners through the EthiQal medical malpractice book), and institutions and corporates (guarantees, liability, specialty P&C, motor and property). Business was written in South Africa and, at the time of the curatorship, in 19 African countries in total including South Africa. The Star newspaper (2 August 2022) and the H1 FY2022 interim report both give this footprint.
Independent characterisation
As an analyst, I would describe Conduit before 2022 as a leveraged bet on an under-capitalised niche insurer, paired with a concentrated small-cap equity portfolio. The pairing hurt the group. Constantia's underwriting turnaround (FY2022 combined ratio below 100% and the first net underwriting profit since 2016, per the 13 June 2024 trading statement) kept being offset by mark-to-market losses in the listed portfolio. The insurer's solvency also depended on external recapitalisation that never arrived: the Trustco/LSH deal (2019–2020) and the Mmuso Consortium deal (2021–2022) both failed. After July 2022, Conduit stopped being an operating insurance group. What remains is a residual holding company. Its value depends on (a) recovering an arbitration award of R50 million plus interest against Trustco Property Holdings, (b) disposing of or transferring the run-off life insurer CLL, and (c) the outcome of a R37.4 million claim from the CICL liquidators.
Strategy
Stated strategy (IAR22 and quarterly reports, 2024–2025)
Management's strategy is defensive and focused on recovery. It has five stated themes:
Realise assets and reduce operating expenses: This is the "short-term strategy", repeated in every quarterly progress report from 2024 to 2025.
Treat the remaining insurance businesses as non-core: After the CICL liquidation, the group no longer has the scale to carry their regulatory costs. They are to be sold or restructured.
Cut operating costs by about 80%: once the planned transactions are complete. IAR22 presents this as the group's only quantified target.
Resolve disputes with the CICL liquidators: and pursue the recovery of assets owed to the group, especially the Trustco arbitration award.
Minimise expenditure: to maximise what is realised from the assets.
IAR22 explicitly states that a favourable short- to medium-term outcome is not guaranteed and that the outlook is uncertain.
Initiatives in the last 24 months (October 2024 – October 2026)
| Initiative | Date | Status |
|---|---|---|
| Disposal of CRIH and CLL to TMM for R55 million | Terms May 2023; FST win 20 Nov 2024 | Lapsed 20 May 2025 after the Prudential Authority confirmed its refusal and TMM chose not to challenge |
| Section 50 transfer of CLL's liabilities and matching assets to a licensed insurer | Raised 30 Sep 2025 | Under consideration; the company says it lacks surplus capital to support new business at CLL |
| Enforcement of the AFSA award against Trustco Properties (R50m plus interest from 10 Dec 2020) | Ongoing since June 2024 | Enforcement steps continuing; no recovery announced |
| Defence of the R37.4m claim by the CICL liquidators | From 3 Sep 2025 | Being defended; the board considers it immaterial |
| Publication of H1 FY2023 and FY2023 results | 2024–2025 | Halted 30 Sep 2025 pending the litigation |
| Board renewal after the resignations | From 19 Sep 2025 | Replacement process started; no appointments disclosed |
| ESG or sustainability commitments | IAR22 | General SDG alignment only (SDGs 3, 5, 7, 8, 9, 10, 12, 13, 16, 17); no targets |
No medium-term financial guidance has been issued.
Products & Services
All Constantia short-term products listed below stopped being written in July 2022, when the Prudential Authority barred new business. The catalogue is historical unless marked otherwise.
Pricing models were not publicly disclosed for any product. Constantia used solvency relief reinsurance extensively. This is a structural feature of the product economics rather than a product. Under these arrangements Constantia ceded "marginally profitable" gross premium in exchange for lower capital requirements. In FY2019, for example, net written premium was R387.9 million as reported, against R1,948.9 million before solvency reinsurance (FY2019 results).
Product Portfolio
| Segment | Product / offering | Description | Target customer | Status |
|---|---|---|---|---|
Health | Medical gap cover and primary health products | Short-term health covers that sit alongside medical scheme membership. Health was the largest line at 54% of H1 FY2022 gross premium | Individuals, through UMAs and brokers | Ceased (CICL liquidation) |
Health | Medical evacuation (through Oraclemed) | Medical evacuation cover across Africa, underwritten by CICL through the Oraclemed underwriting manager | Corporates and travellers in Africa | Oraclemed moved to a replacement insurer |
Medical Malpractice | EthiQal | Professional indemnity for medical practitioners. Gross premium grew 12.9% in H1 FY2022 | Doctors and specialists | Ceased under CICL |
P&C Specialty | Guarantee and indemnity | Guarantee products (gross premium R33.5m in FY2020) | Corporates and contractors | Ceased |
P&C Specialty | Liability | Liability insurance (gross premium R205.0m in FY2020) | Businesses and professionals | Ceased |
P&C Specialty | Other specialty | Grew 20.6% in H1 FY2022 with a gross loss ratio of 46.0% | Niche commercial | Ceased |
P&C General | Motor and property | Personal and commercial motor and property. Being remediated in 2020–2022 (combined ratio 140.5% in H1 FY2022) | Individuals and SMEs | Ceased |
Assistance | Assistance products | Gross premium R130.4m in FY2020 | Policyholders through binder partners | Ceased |
Life | Funeral cover | Funeral insurance. Constantia exited the funeral parlour market in December 2020 | Individuals | CLL in run-off |
Life | Group risk / life cover | Group risk line (gross premium R50.9m in FY2019) | Employer groups | Run-off |
Private investments | Century 21 South Africa | Master franchise for a global real estate brokerage brand; 49 franchises at 31 Dec 2021; annualised return on capital 62.6% (H1 FY2022) | Real estate franchisees | Status not disclosed after 2022 |
Conduit Ventures | Fixico SA | Digital platform for insurers, fleet owners and car owners to manage car damage claims | Insurers and fleets | Minority stake; status not disclosed |
Conduit Ventures | Rikatec | Insurtech in information management, digital solutions, big data and analytics | Insurers | Minority stake; status not disclosed |
Conduit Ventures | Leymic Holdings | Insurance-related holding (named in H1 FY2022) | — | — |
“—” = not publicly disclosed.
Financial Narrative
Disclosure limitations
The five most recent fiscal years with published group results are FY2018 to FY2022. FY2023 to FY2025 have not been published. The FY2022 group statements were disclaimed by Nexia SAB&T, because the CICL liquidators did not prepare audited CICL accounts. The company-level FY2022 statements were neither qualified nor disclaimed (IAR22, shareholders' letter). Insurance accounting does not use gross profit, EBITDA, capex intensity or a cash conversion cycle in any meaningful way, and Conduit did not report them. They are therefore blank.
Income statement and per-share data
Sources: - FY2018 and FY2019 premium and underwriting figures: FY2019 results, Table on Constantia's performance.
-
FY2019 and FY2020 GWP and per-share figures: FY2020 provisional results SENS (2 Nov 2020) and FY2020 results PDF.
-
FY2020 operating loss: FY2020 results table, last two columns. The column layout of the extracted table could not be fully verified.
-
FY2021 and FY2022 total income, attributable income, EPS, HEPS, DPS and market capitalisation: ShareData company page, "12 months ended Jun 2022 (published 30 Aug 24)".
-
The FY2022 ranges in the 13 June 2024 trading statement (LPS 44.19c–48.41c; HLPS 29.64c–33.76c) are consistent with the final figures.
-
The FY2021 GWP is not available in the sources reviewed.
Interim comparison (most granular recent disclosure)
Source: Interim results H1 FY2022 (six months to 31 Dec 2021 vs 31 Dec 2020).
Balance sheet
Source: Interim results H1 FY2022: The balance sheet as at 30 June 2022 (FY2022) is in IAR22 from page 40. Those pages could not be extracted in this research pass, so total assets, debt, net debt, goodwill and working capital at FY2022 are not reported here. They should be taken directly from IAR22 if needed.
The negative consolidated equity at 31 December 2021 is the single most important balance sheet fact. It shows that CICL's regulatory capital shortfall had already spread to the consolidated group before the regulator intervened. At the same date CICL's provisional SCR cover ratio was −0.09 and its MCR cover ratio −0.89. CLL's SCR cover was 2.28 (Interim H1 FY2022).
Net asset value per share (historical)
Sources: SENS trading statement 12 Sep 2017 (FY2016 restated NAV); FY2017 audited results. At 31 December 2017 NAV was guided at 186.1c–190.9c (SENS 20 Feb 2018). No NAV per share is published for any later period; equity attributable to the parent was negative by 31 December 2021.
Cash flow
Source: Interim results H1 FY2022. Conduit did not pay dividends or buy back shares in FY2021 or FY2022 (ShareData shows nil DPS). Capital expenditure is not a meaningful metric for this business.
Ratios
Calculated. Revenue CAGR: Constantia GWP grew at a compound 17.2% per year from FY2018 to FY2020 (R1,536.9m to R2,110.0m). GWP grew 43.6% from FY2017 (R1.07bn) to FY2018.
ROE, ROA, ROIC and debt/equity are not meaningful: equity was negative in December 2021. Interest coverage, net debt/EBITDA, the current ratio, asset turnover and the cash conversion cycle were not disclosed and cannot be calculated from the sources retrieved.
Commentary
Premium growth without capital. Constantia doubled gross written premium from 2017. Gross premium reached R2.1 billion in FY2020. However, the growth was financed largely by solvency relief reinsurance, not by equity. Underwriting losses widened from −R128.6 million (FY2018) to −R259.4 million (FY2019). By FY2019, Constantia's loss after tax was R582 million on net assets of R699 million (Trustco SENS, 11 Feb 2020).
Turnaround (FY2020–FY2022). After management was replaced in February 2020, loss-making books were cancelled. Gross premium fell 14.4% in H1 FY2021 and then grew again. By FY2022, gross written premium was up 8.3% and the combined ratio was below 100%. The trading statement describes this as the first net underwriting profit since 2016. Loss per share narrowed from 92.8c (FY2019) to 21.1c (FY2021).
FY2022 inflection. The FY2022 attributable loss more than doubled to R318.5 million. The cause was R225.0 million (32.7c per share) of impairments and write-downs linked to the CICL liquidation, recognised in FY2022 as events after the reporting date. Mark-to-market losses on the listed portfolio also contributed (IAR22). Investment losses were the main recurring drag throughout: −R33.3 million in H1 FY2021 and −R46.4 million in H1 FY2022, against roughly break-even insurance operations.
Post-FY2022. From August 2022 the group consolidates only one month of CICL. Management guided that completing the planned disposals would cut operating costs by about 80% (IAR22). That outcome is now in doubt, because the TMM disposal lapsed in May 2025.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Ownership | Role | Status |
|---|---|---|---|
Conduit Capital Limited | Holding company | Investment holding | Active; unlisted since 19 Dec 2025 |
Constantia Risk and Insurance Holdings (Pty) Ltd (CRIH) | 100% | Intermediate insurance holding company | Active; holder of the R50m Trustco award |
Constantia Insurance Company Limited (CICL) | 100% (control lost July 2022) | Short-term insurer; about 94.4% of group revenue in H1 FY2022 | In liquidation since 14 Sep 2022 |
Constantia Life Limited (CLL) | 100% | Long-term insurer | Run-off; no new business since 2019 (Moonstone). Section 50 transfer under consideration |
Constantia Life & Health Assurance Company Ltd (CLAH) | 100% | Long-term insurer | Sale to Affinity Financial Services for R20m announced Dec 2022; completion not confirmed |
Copper Sunset Trading 186 (Pty) Ltd | 100% | Holding vehicle and party to the TMM sale | Active |
Conduit Ventures (Pty) Ltd | 100% | Holds insurtech and insurance-related minority stakes (Fixico SA, Rikatec, Leymic Holdings) | Winding-up application dismissed Aug 2024 |
Century 21 South Africa | 51% | Real estate master franchise | Status after 2022 not publicly disclosed |
ASOC Fund I LP | Minority LP interest | Special situations fund launched 2017 | Status not disclosed |
Oraclemed Health Investments | 30% (via Constantia) | Underwriting manager for medical evacuation in Africa | Found a replacement carrier after the CICL liquidation (Moonstone) |
Segment Revenue
| Segment (gross premium, ZAR Mn) | H1 FY2021 | H1 FY2022 |
|---|---|---|
Health | 513.6 | 557.5 |
Medical Malpractice (EthiQal) | 104.9 | 118.4 |
P&C Specialty | 180.0 | 217.1 |
P&C General | 129.1 | 108.3 |
Funeral and Assistance | 27.2 | 23.3 |
Total gross premium | 954.8 | 1,024.6 |
Revenue by Segment (%)
| Segment (% of gross premium) | H1 FY2021 | H1 FY2022 |
|---|---|---|
Health | 53.8 | 54.4 |
Medical Malpractice | 11.0 | 11.6 |
P&C Specialty | 18.9 | 21.2 |
P&C General | 13.5 | 10.6 |
Funeral and Assistance | 2.9 | 2.3 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment combined ratio (%)
| Segment combined ratio (%) | H1 FY2021 | H1 FY2022 |
|---|---|---|
Health | 92.5 | 92.1 |
Medical Malpractice | 82.3 | 85.6 |
P&C Specialty | 101.2 | 99.9 |
P&C General | 115.8 | 140.5 |
Funeral and Assistance | 133.1 | 119.2 |
Group before solvency reinsurance cost | 98.0 | 98.7 |
Group after solvency reinsurance cost | 99.8 | 100.4 |
Revenue by Segment
| Sub-segment GPI (ZAR Mn) | FY2019 | FY2020 | FY2021 |
|---|---|---|---|
P&C Specialty | 202 | 293 | 337 |
P&C General | 483 | 277 | 221 |
EthiQal (Medical Malpractice) | 156 | 204 | 215 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBusiness Lines
| Line (ZAR Mn) | FY2019 | FY2020 |
|---|---|---|
Assistance — gross premium | 76.2 | 130.4 |
Assistance — underwriting result | -30.5 | -18.6 |
Guarantee — gross premium | 30.0 | 33.5 |
Guarantee — underwriting result | 4.0 | 10.9 |
Liability — gross premium | 181.6 | 205.0 |
Liability — underwriting result | 27.5 | 30.8 |
Key Financials and Per-Share Data
| Metric | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
Constantia gross written premium (ZAR Mn) | 1,536.9 | 2,050.7 | 2,110.0 | — | — |
Net written premium as reported (ZAR Mn) | 392.5 | 387.9 | — | — | — |
Net written premium before solvency reinsurance (ZAR Mn) | 1,273.3 | 1,948.9 | — | — | — |
Constantia net underwriting result incl. solvency reinsurance (ZAR Mn) | -128.6 | -259.4 | — | — | — |
Group total income (ZAR Mn) | — | — | — | 1,122.6 | 1,138.0 |
Operating loss as reported (ZAR Mn) | — | -671.8 | -608.0 | — | — |
Attributable income (ZAR Mn) | — | — | — | -145.8 | -318.5 |
Basic EPS (ZAR cents) | — | -92.8 | -80.7 | -21.1 | -46.3 |
Headline EPS (ZAR cents) | — | -88.7 | -77.6 | -20.6 | -31.7 |
Dividend per share (ZAR cents) | — | — | — | 0 | 0 |
Market capitalisation at year end (ZAR Mn) | — | — | — | 413.0 | 289.1 |
Balance Sheet and Per-Share Data
| Metric (ZAR Mn unless stated) | H1 FY2021 | H1 FY2022 |
|---|---|---|
Gross premium | 954.8 | 1,024.6 |
Operating profit or loss from insurance operations | 1.8 | -4.4 |
Net non-insurance loss | -15.8 | -13.3 |
Operating loss | -14.0 | -17.8 |
Investment loss | -33.3 | -46.4 |
Loss before taxation | -54.4 | -74.8 |
Loss for the period | -50.1 | -76.3 |
Loss attributable to equity holders | -51.8 | -76.6 |
Headline loss | -58.2 | -76.2 |
Basic loss per share (ZAR cents) | -7.5 | -11.1 |
Headline loss per share (ZAR cents) | -8.4 | -11.1 |
Balance Sheet
| Metric (ZAR Mn) | 30 Jun 2021 | 31 Dec 2020 | 31 Dec 2021 |
|---|---|---|---|
Total assets | 1,408.8 | 1,568.8 | 1,463.2 |
Cash and cash equivalents | — | 93.7 | 179.3 |
Listed investments at fair value | — | — | 125.2 |
Unlisted investments at fair value | — | — | 24.2 |
Total equity | — | — | -59.3 |
Equity attributable to owners of parent | — | — | -58.5 |
Insurance float | — | — | 618.2 |
Per-Share Data
| Metric | FY2016 | FY2017 |
|---|---|---|
NAV per share (ZAR cents) | 169.5 | 176.1 |
Key Financials
| Metric (ZAR Mn) | H1 FY2022 |
|---|---|
Operating cash inflow | 34.3 |
Net float generated in period | 55.1 |
Margin Analysis (%)
| Ratio | FY2021 | FY2022 |
|---|---|---|
Net margin on total income (%) | -13.0 | -28.0 |
Total income growth (%) | — | 1.4 |
Attributable loss growth (%) | — | -118.5 |
Region Overview
| Region | Description | Source |
|---|---|---|
South Africa | Primary market for all lines, and the domicile of all insurance licences | IAR22; Interim H1 FY2022 |
Rest of Africa | Business written in 18 other African countries, including medical evacuation through Oraclemed | Interim H1 FY2022; The Star, 2 Aug 2022 |
Namibia | No operating revenue. This was the location of the Herboths land asset in the failed Trustco transaction and of the counterparty to the arbitration award | Trustco SENS 11 Feb 2020 |
United States | No revenue. Several former directors (Riskowitz, Maizey, Solberg) were linked to US-based investment managers | IAR22 |
Region revenue (ZAR Mn) | FY2020 | FY2021 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Listing status | Removed from the JSE on 19 Dec 2025 | JSE SENS 11 Dec 2025 |
Suspension | From 21 Sep 2022 | JSE SENS 11 Dec 2025 |
Last traded price before suspension | About 4c (closed at 4c after a 33% fall in early September 2022) | Business Report, 8 Sep 2022 |
Price reaction to curatorship (1 Aug 2022) | Fell about 52% intraday to about R0.17; about 73% down over the prior three years | The Star, 2 Aug 2022 |
Alternative report | Fell from 35c to 18c on the curatorship news | TradingView summary |
Historical reference | R2.98 per share (September 2016; about 539m shares) | Value Investors Club, 27 Sep 2016 |
Market capitalisation (ZAR Mn) | FY2021 | FY2022 |
Market cap | 413.0 | 289.1 |
Capital Markets
| Item | Disclosure |
|---|---|
P/E, EV/EBITDA, EV/Sales | Not meaningful (loss-making; no current price) |
P/B | Not meaningful (negative equity at 31 Dec 2021) |
Analyst consensus | None identified |
Dividends | Nil in FY2021 and FY2022 (ShareData). |
Buyback authority | General authority sought at the 1 Oct 2024 AGM (special resolution 1). Directors stated no specific intention to repurchase. Inoperable once delisted under JSE rules |
Treasury shares | 76.168m (Interim H1 FY2022) |
Credit ratings | GCR (22 May 2017): BBB(ZA) long-term and A3(ZA) short-term national scale, outlook Stable; international scale B+, outlook Negative. Current status not disclosed; presumably lapsed. No Moody's, S&P or Fitch ratings |
Analyst Conclusions
Management guidance
The only guidance is qualitative. Management intends to realise assets, reduce operating costs (by about 80% if the disposals complete), resolve disputes with the CICL liquidators and enforce the Trustco award. IAR22 warns that a favourable outcome in the short to medium term is not guaranteed. No consensus forecasts exist.
Bull case
-
Recoveries could be large relative to the share price. If the R50m-plus-interest Trustco award is collected, the gross amount could be more than 1.6 times the last market capitalisation of R30.6m. The award has been running interest since December 2020.
-
The legal position has held up so far. Conduit defeated the 2024 winding-up applications with costs, won the arbitration, and won at the Financial Services Tribunal (November 2024).
Bear case
-
No audited information since FY2022. Results work has been halted indefinitely. Shareholders cannot value the company, and the delisting removes JSE oversight and price discovery.
-
The regulator is blocking exits. The Prudential Authority has refused CLL's buyer twice. CLL's run-off costs keep consuming scarce cash, and the company admits it lacks surplus capital.
-
Litigation could grow. Beyond the current R37.4m claim, the CICL liquidation involves allegedly missing funds (about R156–160m reported) and large policyholder claims (R580m reported). Further claims against Conduit or former management cannot be ruled out. Board depletion in September 2025 weakens the company's capacity to respond.
Catalysts and monitorables (next 12 months)
| Monitorable | Why it matters |
|---|---|
| Judgment or settlement in the R37.4m CICL liquidators' claim | It is the stated gate for resuming results work |
| Collection or settlement of the Trustco Properties award | The largest potential cash inflow |
| Prudential Authority approval of a Section 50 transfer of CLL | Removes run-off costs and capital burden |
| Appointment of new independent directors and an Audit & Risk chair | Basic governance |
| Publication of H1 FY2023 and FY2023 results | Restores information to shareholders |
| Final winding-up of CICL and any liquidation dividend or claims | Determines the final contingent exposure |
| Any shareholder communication from the unlisted company | Communication channel uncertain after delisting |
Analyst verdict
Conduit Capital is no longer an investable operating company in any conventional sense. It is a residual legal and administrative vehicle left behind by a failed insurance group. The strategy pursued from 2015 to 2022 combined a rapidly growing, thinly capitalised niche insurer with a concentrated value-investing equity portfolio. That combination left almost no margin for error. Constantia doubled its premium base on the back of solvency relief reinsurance, not equity capital. Underwriting losses peaked at about R259 million in FY2019. By December 2021, CICL's solvency cover was negative and consolidated equity had turned negative. Two attempts at recapitalisation failed: the Trustco/LSH structure in 2020 and the R500 million Mmuso deal in 2022. The Prudential Authority's intervention in July 2022 followed. Management's underwriting turnaround was real, but it came too late, and the regulator was evidently unconvinced by it.
What remains has binary value. On one side are contingent assets: a R50 million-plus-interest arbitration award against a Namibian counterparty, a solvent but sub-scale run-off life insurer, and minority stakes of uncertain value. On the other side are contingent liabilities arising from the CICL liquidation, a regulator that has twice blocked an exit, and a board reduced to four members after September 2025. The decision to suspend all financial reporting until the liquidators' claim is resolved means shareholders cannot assess solvency or net asset value. The JSE removed the listing because Conduit failed to remedy its non-compliances, and the company did not appeal. That suggests the board itself saw little realistic prospect of restoring compliance.
For anyone still holding shares, the investment case rests on the legal recoveries exceeding the claims plus the cost of running off and transferring CLL. On the public record, the likely outcome cannot be assessed with confidence. On the evidence available, the position should be treated as a speculative, illiquid litigation claim of uncertain value. It is not a going-concern equity. For competitive intelligence purposes, Conduit and Constantia are now relevant mainly as a case study in South African prudential enforcement, not as a market participant.
Data gaps and discrepancies
| Item | Issue |
|---|---|
| FY2023 to FY2025 financials | Not published; work halted 30 Sep 2025 |
| FY2022 balance sheet and cash flow detail | In IAR22 pages 40–128; not extractable in this research pass |
| Share count | AGM notice (105.1m listed) conflicts with the interim report (764.4m issued; 688.3m outstanding) |
| Date of loss of control of CICL | "End of July 2022" (IAR22; SENS 28 Jun 2024) vs "end of July 2023" (SENS 30 Sep 2024; 30 Jun 2025). 2022 is consistent with the curatorship date |
| Riskowitz resignation date | 21 Jul 2022 (IAR22) vs May 2022 (Business Day) |
| Riskowitz shareholding | 4.47% (MarketScreener) is inconsistent with the company's share count |
| CLAH sale to Affinity | Completion not confirmed |
| Top shareholders and executive pay | In IAR22 (page 127; note 42); not extracted |
| Competitor and market-size figures | deliberately omitted |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Age* | Education | Background |
|---|---|---|---|---|---|
Melvyn Lubega | Independent non-executive Chairman (since 1 Oct 2023); chairs the Remuneration & Nomination Committee; member of Audit & Risk, Investment, and Social & Ethics Committees | 15 March 2021 | 34 | BBusSc (UCT); MSc and MPP (Oxford, Rhodes Scholar) | Actuary by training; entrepreneur and investor; board member of Adcorp Holdings (JSE: ADR) committees |
Leo Chih Hao Chou | Chief Executive Officer (since 1 Oct 2023); previously non-executive director | 9 October 2017 | 43 | BCom (UNISA) | Long-serving board member through the Riskowitz era; Investment and Remuneration Committee member |
Lourens Erasmus Louw | Financial Director (reappointed 1 Jan 2023) | Joined June 2003; FD from October 2004 | 53 | BCom (Stellenbosch); member of the SA Institute of Stockbrokers | Former FD and compliance officer of Irish & Menell Rosenberg (Appleton Group); Constantia Group CFO from February 2021 |
Geoffrey Edgar Bolton Hacking | Independent non-executive director; Lead Independent Director (since 29 Sep 2023); chairs Social & Ethics; member of Audit & Risk (from 30 Aug 2024) | 3 April 2023 | 65 | MBChB (UCT); FF Rad (D) (SA); FRCR (London) | Radiologist and former director of Morton & Partners Radiologists; value investor with more than 45 years' experience |
Board of Directors — Sean Michael Riskowitz
| Name | Role | Tenure | Notes |
|---|---|---|---|
Sean Michael Riskowitz | CEO and executive director | 31 Jul 2015 – 21 Jul 2022 | BCom (Wits); founder of Riskowitz Capital Management and Protea Asset Management. Discrepancy: IAR22 gives a resignation date of 21 July 2022; Business Day (29 Jan 2024) reported May 2022 |
Peter Goeffrey Todd | CEO (21 Jul 2022 – 1 Oct 2023); then executive director until 19 Sep 2025 | 2022 – 2025 | BCom LLB (UCT); former Chief Executive of Mutual & Federal; past President of the Insurance Institute of SA; co-founder of Repair Solutions; Constantia CEO from 2020 |
Christian Richard Solberg | Independent non-executive director; Audit & Risk Committee chair; Investment Committee chair | 3 Apr 2023 – 19 Sep 2025 | Co-founder of Sun Mountain Partners (Boston); BA (Middlebury), MBA (MIT) |
Ronald Stuart Napier | Independent non-executive Chairman | 31 Mar 2015 – 17 Nov 2022 | MA (Oxon) |
Nonzukiso Siyotula | Lead Independent Director; Audit & Risk chair | 24 Mar 2020 – 9 Dec 2022 | CA(SA), ACMA, MBA |
Adrian John Maizey | Non-executive director; Investment Committee chair | 20 Feb 2017 – 18 Jul 2022 | CFO and President of Protea Asset Management; MBA (Harvard), CPA (USA) |
Bianca Yan | Financial Director | 5 Feb 2021 – 31 Dec 2022 | CA(SA) (Wits) |
Directors' Remuneration
| Committee | Members (FY2022) | Meetings attended |
|---|---|---|
Audit & Risk | N Siyotula (Chair), RS Napier, M Lubega | 3 each |
Social & Ethics | N Siyotula (Chair), M Lubega, SM Riskowitz | 2 each |
Nomination | RS Napier (Chair), M Lubega, N Siyotula | 0 |
Remuneration | M Lubega (Chair), RS Napier, N Siyotula, LCH Chou | 1 each |
Investment | AJ Maizey (Chair), M Lubega, SM Riskowitz, LCH Chou | 3 each |
Directors' Remuneration — Non-executive director fees, FY2024
| Item | Disclosure |
|---|---|
Non-executive director fees, FY2024 | Flat R10,000 per non-executive director (Chairman, committee chairs and members alike), excluding VAT (IAR22, AGM special resolution 3) |
Executive incentive structure (policy) | STI plus LTI (50% cash and 50% equity, three-year rolling). Combined incentive cap for non-CEO executives: 0–90% of basic salary. CEO cap: 0–202.5% of basic salary |
Proposed changes ("in principle") | Option to take salary in shares; NAV high-water mark; five-year LTI period; malus and clawback; "Accelerated Buy-in" LTI structure |
Individual executive pay (salary, bonus, total) | Disclosed in note 42 of IAR22 (page 94). |
Service contracts | Six-month notice period; restraint of trade of up to two years; some contracts carry minimum employment periods of two to four years |
Major Shareholders
| Holder | Stake | Source / note |
|---|---|---|
Treasury shares (held by group) | 76.168m shares (about 10.0% of 764.444m issued) | Interim H1 FY2022 |
Sean Riskowitz (former CEO) | 23,073,592 shares (4.47%, as stated by aggregator) | MarketScreener, data dated Aug 2025. Discrepancy: 4.47% implies about 516m shares outstanding, against 688.3m outstanding per company disclosure |
Major shareholders list | Published on IAR22 page 127 | — |
Directors' interests | Published in IAR22 note 50 (pages 121–122) | — |
Competitive Landscape
Competitors by Segment
| Constantia segment | Competitors (illustrative) | Positioning of Constantia |
|---|---|---|
Health (gap cover, primary health) | Other gap cover and health insurance product carriers and UMAs in South Africa | Largest Constantia line (about R1.1bn annualised gross premium); combined ratio about 92% |
Medical malpractice | Medical Protection Society (a discretionary mutual) and other indemnity providers | EthiQal was a disruptive insured alternative; gross premium about R237m annualised |
P&C Specialty (guarantee, liability) | Lombard Insurance, Bryte, Santam Specialist, Guardrisk (cell captive) | Niche, mid-size |
P&C General (motor, property) | Santam, OUTsurance, Old Mutual Insure, Hollard, Discovery Insure | Sub-scale; loss-making (combined ratio 140.5%) |
Funeral and life | Hollard, Old Mutual, Sanlam, Assupol, AVBOB | Sub-scale; exited funeral parlours 2020 |
Listed investment holding companies (value style) | Other small JSE investment holding companies | Discount to NAV; concentrated portfolio |
Benchmark (FY2022 or latest) | Revenue (R m) | Revenue growth (%) |
Conduit Capital | 1,138.0 | 1.4 |
Recent Developments
Very few public disclosures have been made since the December 2025 delisting, so this register covers the full suspension period from 2024 onward. As an unlisted company, it no longer has to publish on SENS.



